These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 7632462)

  • 1. Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
    Jurriaans S; Weverling GJ; Goudsmit J; Boogaard J; Brok M; Van Strijp D; Lange J; Koot M; Van Gemen B
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):473-9. PubMed ID: 7632462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
    DeGruttola V; Beckett LA; Coombs RW; Arduino JM; Balfour HH; Rasheed S; Hollinger FB; Fischl MA; Volberding P
    J Infect Dis; 1994 Apr; 169(4):713-21. PubMed ID: 8133085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?
    Jurriaans S; Van Gemen B; Weverling GJ; Van Strijp D; Nara P; Coutinho R; Koot M; Schuitemaker H; Goudsmit J
    Virology; 1994 Oct; 204(1):223-33. PubMed ID: 7916514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
    Mulder JW; Lange JM; de Wolf F; Houweling JT; Bakker M; Coutinho RA; Goudsmit J
    Neth J Med; 1990 Aug; 37(1-2):4-10. PubMed ID: 2120599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
    Pedersen C; Cooper DA; Brun-Vézinet F; Doherty R; Skinhøj P; Pérol Y; Lüthy R; Leibowitch J; Habermehl KO; Varnier OE
    AIDS; 1992 Aug; 6(8):821-5. PubMed ID: 1418778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
    Loveday C; Kaye S; Tenant-Flowers M; Semple M; Ayliffe U; Weller IV; Tedder RS
    Lancet; 1995 Apr; 345(8953):820-4. PubMed ID: 7534858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma.
    Cao Y; Ho DD; Todd J; Kokka R; Urdea M; Lifson JD; Piatak M; Chen S; Hahn BH; Saag MS
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):353-61. PubMed ID: 7786581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HIV type 1 RNA plasma viremia, p24 antigenemia, and unintegrated DNA as viral load markers in pediatric patients.
    Bush CE; Donovan RM; Manzor O; Baxa D; Moore E; Cohen F; Saravolatz LD
    AIDS Res Hum Retroviruses; 1996 Jan; 12(1):11-5. PubMed ID: 8825613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
    Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
    Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative relationship of circulating p24 antigen with human immunodeficiency virus (HIV) RNA and specific antibody in HIV-infected subjects receiving antiretroviral therapy. The RV43 Study Group.
    Brown AE; Vahey MT; Zhou SY; Chung RC; Ruiz NM; Hofheinz D; Lane JR; Mayers DL
    J Infect Dis; 1995 Oct; 172(4):1091-5. PubMed ID: 7561186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons.
    Bruisten SM; Frissen PH; Van Swieten P; Harrigan PR; Kinghorn I; Larder B; Weigel HM; De Vries E; Regez RM; Henrichs JH; Koot M; Huisman JG
    AIDS Res Hum Retroviruses; 1997 Mar; 13(4):327-35. PubMed ID: 9071432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of HIV-1 p24 antigen by signal-amplification-boosted ELISA of heat-denatured plasma is a simple and inexpensive alternative to tests for viral RNA.
    Schüpbach J
    AIDS Rev; 2002; 4(2):83-92. PubMed ID: 12152521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
    Benson EM; Clarkson J; Law M; Marshall P; Kelleher AD; Smith DE; Patou G; Stewart GJ; Cooper DA; French RA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):105-13. PubMed ID: 10029243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.
    Mofenson LM; Lambert JS; Stiehm ER; Bethel J; Meyer WA; Whitehouse J; Moye J; Reichelderfer P; Harris DR; Fowler MG; Mathieson BJ; Nemo GJ
    N Engl J Med; 1999 Aug; 341(6):385-93. PubMed ID: 10432323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.